The FDA granted  510(k) clearance to Oculus Innovative Sciences, Inc. for Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications.

The Alevicyn SGprescription product, using Microcyn(R) Technology, is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. It may also be used to relieve the pain of first- and second-degree burns and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. Alevicyn SG will launch in the US in July 2015. 

Alevicyn SG Antipruritic Spray Gel has also been cleared for over-the-counter use in the United States. In this use, it is intended to relieve the burning and itching associated with many common types of skin irritation, lacerations, abrasions, and minor burns and is also indicated for the management of irritation and pain from minor burns, including sunburn.